AngioDynamics gets FDA clearance for pulmonary embolism treatment device (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) has secured a label expansion for its AlphaVac F1885 System from the U.S. Food and Drug Administration (FDA).

The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), which affects

AngioDynamicsclearancedeviceembolismFDANASDAQANGOpulmonaryTreatment
Comments (0)
Add Comment